Effects of drug treatment for malignancy on skeletal health of cancer survivors

Ailleen Heras-Herzig, Theresa Guise

Research output: Contribution to journalArticle

Abstract

Cancer treatment has advanced and survivorship is increasing. As such, a new skeletal complication of malignancy, cancer treatment-induced bone loss, has emerged and is likely to be the most common skeletal complication of malignancy in years to come. Therapy for the most common cancers, breast and prostate, often results in sex-steroid deficiency and subsequent bone loss. A significant portion of breast cancers express estrogen receptors, and estrogen stimulates tumor growth. Therapy directed against estrogen action or to reduce estrogen production results in significant survival advantage in women with estrogen receptor-positive breast cancer. This hormonal therapy represents the mainstay of breast cancer treatment and is highly effective. Many breast cancers are also treated with chemotherapy, which often induces transient or permanent ovarian failure. However, estrogen is a critical factor for maintaining bone health and normal bone mineral density. As such, all of these breast cancer therapies may induce bone loss, mainly by reducing estrogen or its action on bone. Aromatase inhibitors fall into this category; its efficacy dictates that it will become first-line therapy for most hormone-sensitive breast cancers. Theoretically, chemotherapy may have direct effects on bone that are independent of the effects of estrogen deficiency, but evidence is lacking. Limited clinical experience indicate that bisphosphonates are effective in preventing bone loss owing to cancer treatment. This article focuses on therapy for breast cancer and other malignancies and the respective contributions of such therapy to bone loss.

Original languageEnglish (US)
Pages (from-to)103-114
Number of pages12
JournalClinical Reviews in Bone and Mineral Metabolism
Volume2
Issue number2
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Survivors
Health
Breast Neoplasms
Pharmaceutical Preparations
Bone and Bones
Estrogens
Neoplasms
Therapeutics
Estrogen Receptors
Drug Therapy
Aromatase Inhibitors
Diphosphonates
Bone Density
Prostatic Neoplasms
Survival Rate
Steroids
Hormones
Survival
Growth

Keywords

  • Antineoplastic drugs
  • Bone
  • Bone loss
  • Malignancy
  • Osteoporosis
  • Skeletal health

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effects of drug treatment for malignancy on skeletal health of cancer survivors. / Heras-Herzig, Ailleen; Guise, Theresa.

In: Clinical Reviews in Bone and Mineral Metabolism, Vol. 2, No. 2, 2004, p. 103-114.

Research output: Contribution to journalArticle

@article{389e64eba0b9428091053a44f88a913f,
title = "Effects of drug treatment for malignancy on skeletal health of cancer survivors",
abstract = "Cancer treatment has advanced and survivorship is increasing. As such, a new skeletal complication of malignancy, cancer treatment-induced bone loss, has emerged and is likely to be the most common skeletal complication of malignancy in years to come. Therapy for the most common cancers, breast and prostate, often results in sex-steroid deficiency and subsequent bone loss. A significant portion of breast cancers express estrogen receptors, and estrogen stimulates tumor growth. Therapy directed against estrogen action or to reduce estrogen production results in significant survival advantage in women with estrogen receptor-positive breast cancer. This hormonal therapy represents the mainstay of breast cancer treatment and is highly effective. Many breast cancers are also treated with chemotherapy, which often induces transient or permanent ovarian failure. However, estrogen is a critical factor for maintaining bone health and normal bone mineral density. As such, all of these breast cancer therapies may induce bone loss, mainly by reducing estrogen or its action on bone. Aromatase inhibitors fall into this category; its efficacy dictates that it will become first-line therapy for most hormone-sensitive breast cancers. Theoretically, chemotherapy may have direct effects on bone that are independent of the effects of estrogen deficiency, but evidence is lacking. Limited clinical experience indicate that bisphosphonates are effective in preventing bone loss owing to cancer treatment. This article focuses on therapy for breast cancer and other malignancies and the respective contributions of such therapy to bone loss.",
keywords = "Antineoplastic drugs, Bone, Bone loss, Malignancy, Osteoporosis, Skeletal health",
author = "Ailleen Heras-Herzig and Theresa Guise",
year = "2004",
doi = "10.1385/BMM:2:2:103",
language = "English (US)",
volume = "2",
pages = "103--114",
journal = "Clinical Reviews in Bone and Mineral Metabolism",
issn = "1534-8644",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Effects of drug treatment for malignancy on skeletal health of cancer survivors

AU - Heras-Herzig, Ailleen

AU - Guise, Theresa

PY - 2004

Y1 - 2004

N2 - Cancer treatment has advanced and survivorship is increasing. As such, a new skeletal complication of malignancy, cancer treatment-induced bone loss, has emerged and is likely to be the most common skeletal complication of malignancy in years to come. Therapy for the most common cancers, breast and prostate, often results in sex-steroid deficiency and subsequent bone loss. A significant portion of breast cancers express estrogen receptors, and estrogen stimulates tumor growth. Therapy directed against estrogen action or to reduce estrogen production results in significant survival advantage in women with estrogen receptor-positive breast cancer. This hormonal therapy represents the mainstay of breast cancer treatment and is highly effective. Many breast cancers are also treated with chemotherapy, which often induces transient or permanent ovarian failure. However, estrogen is a critical factor for maintaining bone health and normal bone mineral density. As such, all of these breast cancer therapies may induce bone loss, mainly by reducing estrogen or its action on bone. Aromatase inhibitors fall into this category; its efficacy dictates that it will become first-line therapy for most hormone-sensitive breast cancers. Theoretically, chemotherapy may have direct effects on bone that are independent of the effects of estrogen deficiency, but evidence is lacking. Limited clinical experience indicate that bisphosphonates are effective in preventing bone loss owing to cancer treatment. This article focuses on therapy for breast cancer and other malignancies and the respective contributions of such therapy to bone loss.

AB - Cancer treatment has advanced and survivorship is increasing. As such, a new skeletal complication of malignancy, cancer treatment-induced bone loss, has emerged and is likely to be the most common skeletal complication of malignancy in years to come. Therapy for the most common cancers, breast and prostate, often results in sex-steroid deficiency and subsequent bone loss. A significant portion of breast cancers express estrogen receptors, and estrogen stimulates tumor growth. Therapy directed against estrogen action or to reduce estrogen production results in significant survival advantage in women with estrogen receptor-positive breast cancer. This hormonal therapy represents the mainstay of breast cancer treatment and is highly effective. Many breast cancers are also treated with chemotherapy, which often induces transient or permanent ovarian failure. However, estrogen is a critical factor for maintaining bone health and normal bone mineral density. As such, all of these breast cancer therapies may induce bone loss, mainly by reducing estrogen or its action on bone. Aromatase inhibitors fall into this category; its efficacy dictates that it will become first-line therapy for most hormone-sensitive breast cancers. Theoretically, chemotherapy may have direct effects on bone that are independent of the effects of estrogen deficiency, but evidence is lacking. Limited clinical experience indicate that bisphosphonates are effective in preventing bone loss owing to cancer treatment. This article focuses on therapy for breast cancer and other malignancies and the respective contributions of such therapy to bone loss.

KW - Antineoplastic drugs

KW - Bone

KW - Bone loss

KW - Malignancy

KW - Osteoporosis

KW - Skeletal health

UR - http://www.scopus.com/inward/record.url?scp=4143153127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143153127&partnerID=8YFLogxK

U2 - 10.1385/BMM:2:2:103

DO - 10.1385/BMM:2:2:103

M3 - Article

AN - SCOPUS:4143153127

VL - 2

SP - 103

EP - 114

JO - Clinical Reviews in Bone and Mineral Metabolism

JF - Clinical Reviews in Bone and Mineral Metabolism

SN - 1534-8644

IS - 2

ER -